Literature DB >> 1254951

Tumor-associated blocking factors: isolation from sera of tumor-bearing mice.

J Tamerius, J Nepom, I Hellström, K E Hellström.   

Abstract

An isolation and partial purifications of tumor-associated blocking factors from the sera of tumor-bearing mice is described. Columns for affinity chromatography were prepared by coupling syngeneic tumor-immune antibodies to Sepharose 4B. Passage of serum through such immunoadsorbent columns removed all blocking activity from tumor-bearers' sera; subsequent elution of the absorbent with 3 M NaSCN recovered the activity. The blocking material was further purified on Sephadex G-200. The data provide evidence for the presence of antigen in tumor-associated blocking factors and are compatible with the hypothesis that blocking factors often consist of antigen and antibodies in the form of immune complexes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1254951

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Activation of alveolar macrophages exposed to lavage-procured immunoglobulin G obtained from normal rabbit lungs.

Authors:  M Ando; M Suga; K Shima; M Sugimoto; H Tokuomi
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

2.  Immunological aspects of cryoprecipitates from the sera of chronic HBsAg carriers.

Authors:  M L Tiku; K R Beutner; P L Ogra
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

3.  Comparison of serum blocking factors on leucocyte adherence inhibition and PHA lymphocyte blastogenesis in breast cancer patients.

Authors:  T Fujisawa; R H Yonemoto; S R Waldman
Journal:  Jpn J Surg       Date:  1981

4.  Correlation between immune complexes and prognostic factors in Hodgkin's disease.

Authors:  P L Amlot; B Pussell; J M Slaney; B D Williams
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

Review 5.  Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?

Authors:  Randall J Brezski; Robert E Jordan
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

6.  Serum inhibitory effect on myeloperoxidase in human cancer.

Authors:  B Senelar; R Michel; J Tournamille; H Vannereau; M J Escola; J Taib; A Craste de Paulet
Journal:  Br J Exp Pathol       Date:  1982-06

7.  Treatment of advanced malignancy with plasma perfused over staphylococcal protein A.

Authors:  F R MacKintosh; K Bennett; S Schiff; J Shields; S W Hall
Journal:  West J Med       Date:  1983-07

8.  Antigen-specific purification of blocking factors from sera of mice with chemically induced tumors.

Authors:  J T Nepom; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

9.  Autosensitization and immune complexes in chronic idiopathic thrombocytopenic purpura.

Authors:  R Clancy; R Trent; V Danis; R Davidson
Journal:  Clin Exp Immunol       Date:  1980-01       Impact factor: 4.330

10.  Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.

Authors:  A M Berghella; P Pellegrini; D Piancatelli; D Maccarone; T Del Beato; D Giubilei; A Pomidori; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.